ERBB2 and breast carcinoma: Many studies have shown that pairing anthracycline-based chemotherapy with trastuzumab can lead to significant AEs such as cardiotoxicity, which has led to a gradual shift from anthracycline-based regimens to paclitaxel-based regimens for the treatment of early-stage HER2+ breast cancer in the clinic.[31] In a phase II trial of trastuzumab combined with vinorelbine for treating advanced HER2+ breast cancer in women, one of 68 subjects developed symptomatic heart failure.